Results for
"[search-keyword]"
Sponsor content
150 result(s) found, displaying 1 to 10
-
Australian Public Assessment Report (AusPAR)Opdivo (nivolumab), in combination with platinum-doublet chemotherapy, has been approved for the neoadjuvant treatment of patients with resectable non-small cell lung cancer.
-
Jul-2024Prescription medicine evaluationActive ingredient: nivolumab.
-
Jul-2024Prescription medicine evaluationActive ingredient: Ipilimumab.
-
Cancellation by sponsorRequested by Bristol-Myers Squibb Australia Pty Ltd
-
Cancellation by sponsorRequested by Bristol-Myers Squibb Australia Pty Ltd
-
May-2024Prescription medicine evaluationActive ingredient: repotrectinib.
-
Mar-2024Prescription medicine evaluationActive ingredient: nivolumab.
-
Prescription medicine registrationActive ingredients: nivolumab.
-
Australian Public Assessment Report (AusPAR)Opdualag (Nivolumab and Relatlimab) has been approved for the treatment of patients with unresectable or metastatic melanoma who are at least 12 years old.
-
Jan-2024Prescription medicine evaluationActive ingredient: nivolumab.